AstraZeneca Makes USD 10 Billion Bid for Obesity Drugmaker Rhythm Pharmaceuticals
Written By : sheeba farhat
Published On 2026-11-06 13:15 GMT | Update On 2026-11-06 13:15 GMT
Bengaluru: AstraZeneca made an about USD 10 billion offer to acquire obesity drugmaker Rhythm Pharmaceuticals, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
The British drugmaker offered about $124 per share for Rhythm last month, the report said.
Shares of Rhythm closed up 28% at $110.68 on the news, giving it a market capitalization of about $7.64 billion, according to LSEG data.
AstraZeneca had previously expressed interest in Rhythm, which develops treatments for rare metabolic disorders and severe obesity, and renewed its pursuit in recent months, the report added.
AstraZeneca declined to comment, while Rhythm did not immediately respond to requests for comment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.